<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03654573</url>
  </required_header>
  <id_info>
    <org_study_id>1801</org_study_id>
    <nct_id>NCT03654573</nct_id>
  </id_info>
  <brief_title>The MOCA I Study - Microvascular Obstruction With CoFI™ System Assessment</brief_title>
  <acronym>MOCA</acronym>
  <official_title>The MOCA I Study - Microvascular Obstruction With CoFI™ System Assessment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CorFlow Therapeutics AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>CorFlow Therapeutics AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      First-in-Human study to assess the CoFI™ device related safety and the feasibility of the
      diagnostic and the therapeutic sequence as well as the correlation between the dynamic
      microvascular resistance (dMVR) and microvascular obstruction (MVO) as measured by MRI in
      patients presenting with acute ST-elevation myocardial infarction (STEMI) undergoing
      percutaneous coronary intervention (PCI).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 4, 2019</start_date>
  <completion_date type="Anticipated">March 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>N= 20 Diagnostic and N= 20 Therapeutic</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of study device or study procedure adverse effect or event</measure>
    <time_frame>up to 30 days</time_frame>
    <description>Safety Objective is the incidence of study device or study procedure adverse effect or event at up to 30 days. To assess the CoFI™ device related safety and the feasibility of the diagnostic and the therapeutic sequence as well as the correlation between the dynamic microvascular resistance (dMVR) and microvascular obstruction (MVO) as measured by MRI in patients presenting with acute ST-elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Diagnostic Success</measure>
    <time_frame>0 days</time_frame>
    <description>Ability to perform a diagnostic sequence and to calculate a base flow resistance curve</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Therapeutic Success</measure>
    <time_frame>0 days</time_frame>
    <description>Ability to perform the therapeutic sequence as described in the CIP</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>STEMI - ST Elevation Myocardial Infarction</condition>
  <condition>Microvascular Obstruction</condition>
  <arm_group>
    <arm_group_label>STEMI patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Adult subjects presenting with STEMI in the LAD undergoing PPCI</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>CorFlow Controlled Flow Infusion System - CoFI™</intervention_name>
    <description>The CorFlow CoFI™ System is intended to assess the dynamic microvascular resistance and to treat microvascular obstruction in the coronary vasculature of patients following PCI with stent placement.</description>
    <arm_group_label>STEMI patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Major Inclusion Criteria:

          -  Patients 18 years of age or older presenting with ST-elevation myocardial infarction
             in the left anterior descending artery (LAD) undergoing primary percutaneous coronary
             intervention.

          -  Competent mental condition to provide signed and dated ethics committee approved study
             consent prior to study related procedures

          -  Eligible for prasugrel, ticagrelor, cangrelor, tirofiban, UFH and GP IIb/IIIa
             inhibitors

          -  Referred for primary PCI within 5 hours of symptom onset with evidence of continuing
             ischemia and symptom to balloon time not exceeding 6 hours

        Major Exclusion Criteria:

          -  Unconsciousness

          -  Previous bypass graft surgery

          -  Contraindication to CMRI

          -  Recent or current major bleeding within 30 days prior to intervention

          -  Recent major surgery within 30 days prior to intervention

          -  End-stage heart failure with inotrope support and/or consideration for LVAD or heart
             transplant

          -  Transient ischemic attack or stroke within 30 days prior to intervention

          -  Pregnant or females of childbearing potential
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Esther Gerteis</last_name>
    <role>Study Director</role>
    <affiliation>CorFlow Therapeutics AG</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Esther Gerteis</last_name>
    <phone>+41 41 544 55 56</phone>
    <email>egerteis@corflow-therapeutics.ch</email>
  </overall_contact>
  <location>
    <facility>
      <name>Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco Valgimigli, Prof. Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Marco Valgimigli, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HUG Geneva</name>
      <address>
        <city>Geneva</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Juan F. Iglesias, Dr</last_name>
    </contact>
    <investigator>
      <last_name>Juan F. Iglesias, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHUV Lausanne</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephane Fournier, Dr.</last_name>
    </contact>
    <investigator>
      <last_name>Stephane Fournier, Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>August 16, 2018</study_first_submitted>
  <study_first_submitted_qc>August 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2018</study_first_posted>
  <last_update_submitted>April 23, 2020</last_update_submitted>
  <last_update_submitted_qc>April 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 24, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

